Epizyme to Report Third Quarter 2014 Financial Results and Provide Corporate Update on November 6, 2014
October 30 2014 - 08:00AM
Business Wire
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical
company creating innovative personalized therapeutics for patients
with genetically defined cancers, announced today that it will host
a conference call and live audio webcast on Thursday, November
6, 2014, at 8:00 a.m. ET to report third quarter
2014 financial results and provide a corporate update.
To participate in the conference call, please dial
1-877-844-6886 (domestic) or 1-970-315-0315 (international) and
refer to conference ID 27197386. The live webcast can be accessed
under "Events and Presentations" in the Investor Relations section
of the Company's website at www.epizyme.com.
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company
creating personalized therapeutics for patients with genetically
defined cancers. Epizyme has built a proprietary product
platform that the Company uses to create small molecule inhibitors
of a 96-member class of enzymes known as histone
methyltransferases, or HMTs. HMTs are part of the system of gene
regulation, referred to as epigenetics, that controls gene
expression. Genetic alterations can result in changes to the
activity of HMTs, making them oncogenic (cancer-causing). By
focusing on the genetic drivers of
cancers, Epizyme's targeted science seeks to match the
right medicines with the right patients for a personalized approach
to cancer treatment.
For more information, visit www.epizyme.com and
connect with us on Twitter at @EpizymeRx.
Epizyme, Inc.Investors/Media:Manisha Pai,
617-229-7560mpai@epizyme.com
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Mar 2023 to Mar 2024